On September 21, HENGRUI PHARMA rose 3.11% in regular trading to HKD 47.68, with turnover of HKD 74.67 million. The rally follows a cluster of positive catalysts disclosed late last week.

On September 18, the company unveiled a proposed A-share employee stock ownership plan covering up to 1,269 participants with up to 12.855 million repurchased shares (0.19% of total capital), alongside an H-share plan and general H-share buyback authorization. On September 17, the company completed its first A-share buyback of 335,000 shares for RMB 14.5 million at RMB 43.10–43.58 per share, under a broader RMB 1–2 billion buyback program earmarked for employee incentives.

Meanwhile, BlackRock has steadily raised its H-share stake from 5.92% to 7.68% through multiple rounds of accumulation in September, signaling strong institutional conviction. Pipeline momentum also remains robust, with recent milestones including two new approved indications for hetrombopag olamine tablets, a breakthrough therapy designation for its lung cancer ADC, and marketing applications accepted for two innovative drugs.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)